[{"id":"d77f7e27-d759-4800-bb9d-f2404753c9ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT06222593","created_at":"2024-01-24T15:19:20.942Z","updated_at":"2025-02-25T14:10:34.092Z","phase":"Phase 1/2","brief_title":"Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC","source_id_and_acronym":"NCT06222593","lead_sponsor":"State University of New York at Buffalo","biomarkers":" AR • KLK2","pipe":" | ","alterations":" AR expression • KLK2 expression","tags":["AR • KLK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • KLK2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • bicalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2025-02-17"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"ff675977-05eb-4cd0-95e9-0479db1dd928","acronym":"CA209-8H3","url":"https://clinicaltrials.gov/study/NCT03650894","created_at":"2021-01-18T17:55:05.836Z","updated_at":"2025-02-25T14:27:31.343Z","phase":"Phase 2","brief_title":"Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients","source_id_and_acronym":"NCT03650894 - CA209-8H3","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" HER-2 negative • AR positive","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • bicalutamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/03/2019","start_date":" 04/03/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-10-26"},{"id":"41b730ba-cb49-45dd-837c-967e8c4c2b8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03090165","created_at":"2021-01-18T15:13:36.654Z","updated_at":"2025-02-25T15:53:41.650Z","phase":"Phase 1/2","brief_title":"Ribociclib and Bicalutamide in AR+ TNBC","source_id_and_acronym":"NCT03090165","lead_sponsor":"Kari Wisinski","biomarkers":" HER-2 • ER • AR","pipe":" | ","alterations":" HER-2 negative • AR positive • HER-2 negative + ER positive","tags":["HER-2 • ER • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • bicalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 05/07/2018","start_date":" 05/07/2018","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-10-11"},{"id":"63ba93fd-a0f6-4865-ad2d-03267b454c0a","acronym":"S1802","url":"https://clinicaltrials.gov/study/NCT03678025","created_at":"2021-07-05T17:17:10.086Z","updated_at":"2025-02-25T16:31:34.107Z","phase":"Phase 3","brief_title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03678025 - S1802","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" SYP","pipe":"","alterations":" ","tags":["SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • Eligard (leuprolide acetate) • bicalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 1273","initiation":"Initiation: 09/24/2018","start_date":" 09/24/2018","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2024-08-16"},{"id":"4004e195-6fa4-408f-8f56-450ccd6489c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06528210","created_at":"2025-02-25T16:02:53.341Z","updated_at":"2025-02-25T16:02:53.341Z","phase":"Phase 2","brief_title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","source_id_and_acronym":"NCT06528210","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bicalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-07-30"},{"id":"9fe0152c-72e1-4a52-bb9d-c984450578a4","acronym":"ARCH","url":"https://clinicaltrials.gov/study/NCT05700903","created_at":"2023-01-26T15:02:58.180Z","updated_at":"2024-07-02T16:34:26.941Z","phase":"Phase 4","brief_title":"Contributions to Hypertension With Androgen Deprivation Therapy","source_id_and_acronym":"NCT05700903 - ARCH","lead_sponsor":"University of Colorado, Denver","biomarkers":" LCN2","pipe":"","alterations":" ","tags":["LCN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • bicalutamide • goserelin acetate • flutamide • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 228","initiation":"Initiation: 09/20/2023","start_date":" 09/20/2023","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-06-12"},{"id":"c675e0ca-7f1a-4e3c-8775-d10e0e747837","acronym":"","url":"https://clinicaltrials.gov/study/NCT03358563","created_at":"2024-05-03T20:26:05.283Z","updated_at":"2025-02-25T16:31:15.404Z","phase":"Phase 1","brief_title":"Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer","source_id_and_acronym":"NCT03358563","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" AR • EPCAM","pipe":"","alterations":" ","tags":["AR • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • bicalutamide • Firmagon (degarelix)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/17/2018","start_date":" 01/17/2018","primary_txt":" Primary completion: 08/10/2021","primary_completion_date":" 08/10/2021","study_txt":" Completion: 09/02/2022","study_completion_date":" 09/02/2022","last_update_posted":"2024-05-03"},{"id":"acac02cd-c592-4eb3-b05a-a4f2485bc521","acronym":"DUCT","url":"https://clinicaltrials.gov/study/NCT05513365","created_at":"2022-08-24T21:07:35.191Z","updated_at":"2024-07-02T16:35:07.770Z","phase":"Phase 2","brief_title":"Phase II Dutasteride in Combination With CAB vs CAB in SDC","source_id_and_acronym":"NCT05513365 - DUCT","lead_sponsor":"Radboud University Medical Center","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bicalutamide • goserelin acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/27/2022","start_date":" 09/27/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-04-24"},{"id":"df0d825b-2af3-442a-b3f7-5a5b1f7bd370","acronym":"","url":"https://clinicaltrials.gov/study/NCT05095207","created_at":"2021-10-27T15:53:20.401Z","updated_at":"2024-07-02T16:35:18.334Z","phase":"Phase 1/2","brief_title":"Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer","source_id_and_acronym":"NCT05095207","lead_sponsor":"Icahn School of Medicine at Mount Sinai","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • bicalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-02-21"},{"id":"1bd14822-da3c-4dbb-9782-85f6d5deab4b","acronym":"PREDICT-RT","url":"https://clinicaltrials.gov/study/NCT04513717","created_at":"2021-01-18T21:37:58.373Z","updated_at":"2024-07-02T16:35:20.440Z","phase":"Phase 3","brief_title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","source_id_and_acronym":"NCT04513717 - PREDICT-RT","lead_sponsor":"NRG Oncology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate) • Yonsa (abiraterone acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 2478","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 12/31/2033","primary_completion_date":" 12/31/2033","study_txt":" Completion: 12/31/2033","study_completion_date":" 12/31/2033","last_update_posted":"2024-02-07"},{"id":"8a8c1097-2351-4c75-bfab-fe99e5d38d48","acronym":"","url":"https://clinicaltrials.gov/study/NCT02605486","created_at":"2021-01-17T17:26:08.635Z","updated_at":"2024-07-02T16:35:44.260Z","phase":"Phase 1/2","brief_title":"Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)","source_id_and_acronym":"NCT02605486","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" AR expression","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • bicalutamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 11/11/2015","start_date":" 11/11/2015","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-06-30"},{"id":"bac307eb-8b56-473a-95bd-7b6ec2732fb2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00468715","created_at":"2021-01-18T01:39:59.341Z","updated_at":"2025-02-25T15:03:41.417Z","phase":"Phase 2","brief_title":"Bicalutamide in Treating Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT00468715","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • ER • PGR • AR","pipe":" | ","alterations":" AR positive","tags":["HER-2 • ER • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bicalutamide"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 03/23/2007","start_date":" 03/23/2007","primary_txt":" Primary completion: 06/24/2021","primary_completion_date":" 06/24/2021","study_txt":" Completion: 06/24/2021","study_completion_date":" 06/24/2021","last_update_posted":"2022-08-03"},{"id":"782a5ecf-bb65-4e4c-b555-8f76c641cb22","acronym":"","url":"https://clinicaltrials.gov/study/NCT02918968","created_at":"2021-05-21T16:57:57.596Z","updated_at":"2024-07-02T16:36:29.933Z","phase":"Phase 4","brief_title":"Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT02918968","lead_sponsor":"Astellas Pharma Inc","biomarkers":" NKX2-1","pipe":"","alterations":" ","tags":["NKX2-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • bicalutamide • flutamide"],"overall_status":"Completed","enrollment":" Enrollment 206","initiation":"Initiation: 11/02/2016","start_date":" 11/02/2016","primary_txt":" Primary completion: 03/27/2020","primary_completion_date":" 03/27/2020","study_txt":" Completion: 03/27/2020","study_completion_date":" 03/27/2020","last_update_posted":"2021-05-21"},{"id":"a95b6e57-9a71-4897-a32d-ead308f80cf7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02697032","created_at":"2021-01-18T13:09:57.569Z","updated_at":"2024-07-02T16:36:53.136Z","phase":"Phase 2","brief_title":"FDHT PET and Bicalutamide in Metastatic Breast Cancer","source_id_and_acronym":"NCT02697032","lead_sponsor":"University Medical Center Groningen","biomarkers":" HER-2 • AR","pipe":" | ","alterations":" HER-2 negative • AR positive","tags":["HER-2 • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bicalutamide"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 11/25/2019","primary_completion_date":" 11/25/2019","study_txt":" Completion: 11/25/2019","study_completion_date":" 11/25/2019","last_update_posted":"2019-11-27"},{"id":"039db094-9ffb-4f7f-96c3-5b7d000fed8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02910050","created_at":"2021-01-18T14:16:57.455Z","updated_at":"2024-07-02T16:37:15.368Z","phase":"Phase 2","brief_title":"Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer","source_id_and_acronym":"NCT02910050","lead_sponsor":"Xu fei","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • bicalutamide"],"overall_status":"Unknown status","enrollment":" Enrollment 58","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 09/01/2018","primary_completion_date":" 09/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2017-12-22"}]